The Chinese gene-editing experiment was an outrage. The scientific community shares blame.
By J. Benjamin Hurlbut, Sheila Jasanoff and Krishanu Saha,
The Washington Post
| 11. 29. 2018
This is the experiment that was not supposed to happen.
A Chinese scientist claimed this week that he had produced the first genetically engineered babies — twin girls who have been “edited” to be resistant to HIV. He and his collaborators, who apparently include a professor at Rice University in Houston, allegedly applied the genome editing tool known as CRISPR to embryos produced through in vitro fertilization to modify a gene called CCR5. The purpose of the edit was to prevent future HIV infection, a move akin to a genetic vaccination.
Three years ago, scientists, social scientists and ethicists gathered in Washington at the National Academy of Sciences for the first international summit on human gene editing, to discuss scientific, social and ethical issues surrounding human applications of this powerful new tool. One result of the meeting was a call for a voluntary international moratorium on reproductive applications of genome editing until there was “broad societal consensus” about when making such heritable modifications is ethically acceptable.
Nothing remotely like a consensus has been reached, yet the research races ahead. Numerous...
Related Articles
By Aisha Down, The Guardian | 11.10.2025
It has been an excellent year for neurotech, if you ignore the people funding it. In August, a tiny brain implant successfully decoded the inner speech of paralysis patients. In October, an eye implant restored sight to patients who had...
By Jessica Hamzelou, MIT Technology Review | 11.07.2025
This week, we heard that Tom Brady had his dog cloned. The former quarterback revealed that his Junie is actually a clone of Lua, a pit bull mix that died in 2023.
Brady’s announcement follows those of celebrities like Paris...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...